prostate cancer

[Proceedings of the National Academy of Sciences of the United States of America] Investigators showed that EZH2 inhibitors could block the transactivation activity of EZH2 and inhibit the growth of CRPC cells, which revealed a previously unappreciated mechanism of action of EZH2 inhibitors and provided a mechanistic basis for potential combination cancer therapies.

[Cancer & Metabolism] As cholesterol is a key substrate for de novo steroidogenesis in prostate cells, researchers hypothesized that castrate-resistant/advanced prostate cancer cell growth was influenced by the availability of extracellular, low-density lipoprotein (LDL)-derived, cholesterol, which was coupled to intracellular cholesteryl ester homeostasis.

[Expert Opinion On Biological Therapy] The authors present completed and ongoing research projects regarding prostate cancer immunotherapy. Ipilimumab and olaparib were proved to prolong overall survival significantly against placebo, but a lot of research is going on to identify which patients and at what stage of disease will benefit the most before incorporating them in clinical practice.

[Cancer Letters] Scientists summarize the data on the discovery, modeling, molecular taxonomy, lineage plasticity and therapeutic targeting of ETS family members in prostate cancer.

[23andMe Holding Co.] 23andMe Holding Co. received FDA clearance for a genetic health risk report on a hereditary prostate cancer marker.

[Nature Communications] Researchers uncovered heterogeneous cellular states in prostate epithelial cells marked by high androgen signaling states that were enriched in prostate cancer and identified a population of tumor-associated club cells that may be associated with prostate carcinogenesis.